期刊
CANCER TREATMENT REVIEWS
卷 74, 期 -, 页码 29-34出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2019.01.007
关键词
Early breast cancer; Extended adjuvant endocrine therapy; Aromatase inhibitor; Hormone receptor-positive breast cancer; Luminal breast cancer
类别
Patients with luminal early breast cancer are at risk of relapse, even after five years of adjuvant endocrine therapy. To date, no biomarkers have been clinically validated to identify those patients at risk of late recurrence, who might benefit from extended adjuvant endocrine therapy. In recent decades, multiple clinical trials have tested the role of extending adjuvant endocrine therapies in patients with luminal disease. However, the data currently at our disposal are conflicting. This article reviews all the major trials concerning extended adjuvant endocrine regimens, and formulates some general conclusions and hypotheses of future study.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据